GEMP Gemphire Therapeutics Inc.

+0.39  (4%)
Previous Close 10.11
Open 10.14
Price To book 4.24
Market Cap 111.30M
Shares 10,600,000
Volume 18,406
Short Ratio 1.22
Av. Daily Volume 40,455

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated in 2H 2017 with data due 2H 2018.
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
Phase 2b data due early 2018.
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b data due 3Q 2017.
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2b data due June 2017.
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)